"Mainz Biomed partners with Quest for colorectal cancer screening test" was originally created and published by Medical ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert ...

Mainz Biomed’s ColoAlert test has shown promising sensitivity and specificity in identifying colorectal cancer, including advanced adenomas, in preliminary data. Quest will provide clinical trial ...

Our work to minimize our environmental impact starts within our walls. We have taken and continue to take steps to lower our ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $173.75, a high estimate of $185 ...

Shares of Quest Diagnostics Inc. DGX inched 0.18% higher to $151.52 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA ...

questhealth.com offers more than 100 Quest Diagnostics lab tests in categories ranging from heart health and sexual health to allergies, fitness, and so much more. Consumers must be 18+ to ...

Shares of Quest Diagnostics Inc. DGX slipped 0.69% to $155.00 Friday, on what proved to be an all-around mixed trading ...

New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results ... to identify health risks via lab tests, and now they can also engage ...

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people ...

questhealth.com offers more than 100 Quest Diagnostics lab tests in categories ranging from heart health and sexual health to allergies, fitness, and so much more. Consumers must be 18+ to purchase, ...